Pharmaceutical Technology

JULY 26, 2022

NewAmsterdam Pharma has signed a definitive business combination agreement with special purpose acquisition company (SPAC) Frazier Lifesciences Acquisition (FLAC). The deal will make NewAmsterdam Pharma a publicly listed company focusing on oral treatments for cardiometabolic diseases.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

pharmaphorum

OCTOBER 14, 2022

A consortium of industry and academic groups – led by Johnson & Johnson’s pharma division Janssen – has been set up to tackle the environmental impact of digital health products, specifically aimed at minimising waste that could end up in landfill. The project started on 1 October and is scheduled to complete in September 2026.

Leads 121

Leads Electronics Ethics Healthcare 121

pharmaphorum

JULY 26, 2022

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib. Remember CETP? Amgen licensed the rights to NewAmsterdam in 2020.

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

JANUARY 18, 2023

NewAmsterdam Pharma’s bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib. Amgen licensed the rights to NewAmsterdam in 2020.

Pharma 59

Pharma Prospecting Patients Safety 59

European Pharmaceutical Review

AUGUST 22, 2024

1 within the next seven years, the GLP-1R market will “expand to 35 approved products from 16 companies” Jasper Morley, Pharma Analyst at GlobalData noted that these products include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Trulicity and Mounjaro ®. The treatment was also shown to hold a “good safety and tolerability” profile.

Medicine 59

Medicine Marketing Manufacturing Sales 59

pharmaphorum

DECEMBER 21, 2022

Since September, it has been led by president and CEO Sujay Kango – also on the boards of MEI Pharma and Infinity Pharma – who has no doubt focused his attentions on getting the Kite deal over the line since taking on the role. Image by Anja from Pixabay .

Pharma 52

Pharma Manufacturing Engineering Safety 52

PM360

SEPTEMBER 21, 2023

Under the pathway, manufacturers can use safety and efficacy data from existing products in their applications for their own products. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen.

Management 105

Management Manufacturing Sales Competition 105